Aceragen, Inc. Stock Nyse
Equities
ACGN
US00445F1093
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | 4.86M | Capitalization | 3.12M |
---|---|---|---|---|---|
Net income 2021 | 98M | Net income 2022 | -23M | EV / Sales 2021 * | - |
Net cash position 2021 * | - | Net cash position 2022 * | - | EV / Sales 2022 * | - |
P/E ratio 2021 * |
-
| P/E ratio 2022 * |
-
| Employees | 26 |
Yield 2021 * |
-
| Yield 2022 * |
-
| Free-Float | 38.12% |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.08% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |